depressive disorder; dsm-iv
Item
1. depressive disorder diagnostic statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr).
boolean
C0011581 (UMLS CUI [1])
C0220952 (UMLS CUI [2])
major depression; dysthymic disorder; substance-induced mood disorder
Item
2. madras score of 26 or above and history of depression, as defined by meeting dsm-iv criteria for major depression, dysthymic disorder, or substance-induced mood disorder.
boolean
C1269683 (UMLS CUI [1])
C0013415 (UMLS CUI [2])
C3267135 (UMLS CUI [3])
gender; age
Item
3. male or female aged 18 to 65.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Contraception status
Item
4. females who are not pregnant or nursing.
boolean
C0420837 (UMLS CUI [1])
informed consent
Item
5. individuals able to provide informed written consent and are able to comply with study procedures.
boolean
C0021430 (UMLS CUI [1])
antidepressant agents
Item
6. subjects who have received or are receiving anti-depressant medication.
boolean
C0003289 (UMLS CUI [1])
depressive episode
Item
7. patients who are depressed as assessed by the above criteria and have not had optimum response to their antidepressant medication in their current episode.
boolean
C0349217 (UMLS CUI [1])
exclusion criteria
Item
exclusion criteria list
boolean
C0680251 (UMLS CUI [1])
Axis I diagnosis
Item
1. any axis i diagnosis that, in the opinion of the investigators, may interfere with the course of the trial.
boolean
C0270287 (UMLS CUI [1])
alcohol abuse
Item
2. any current diagnoses of alcohol abuse or dependence.
boolean
C0085762 (UMLS CUI [1])
substance use disorder
Item
3. any current substance use disorder.
boolean
C0038586 (UMLS CUI [1])
Compliance behavior Limited Comorbidity
Item
4. medical or neurological illness that in the investigators judgment would make study compliance difficult or would be a contraindication for use with tms.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
tricyclic antidepressants; lidocaine; clozapine
Item
5. currently receiving any medication that markedly increases the risks for seizures, for example: tricyclic antidepressants, inh, meperidine, lidocaine, and clozapine.
boolean
C0003290 (UMLS CUI [1])
C0023660 (UMLS CUI [2])
C0009079 (UMLS CUI [3])
Implants metal; dental implants
Item
6. subjects who have implanted metallic devices or non-removable metallic objects in or around the head that can be magnetized, however metal fillings, braces, and dental implants are acceptable.
boolean
C0021102 (UMLS CUI [1,1])
C0025552 (UMLS CUI [1,2])
C0011373 (UMLS CUI [2])
cardioverter defibrillators; vagus nerve stimulators
Item
7. subjects who have implanted devices that emit physiological signals including cardioverter defibrillators (icds), and vagus nerve stimulators.
boolean
C0810516 (UMLS CUI [1])
C1458051 (UMLS CUI [2])
study drug
Item
8. subjects who have received any investigational drug during the prior 30 days.
boolean
C0013227 (UMLS CUI [1,1])
C0008972 (UMLS CUI [1,2])
laboratory measurement abnormal
Item
9. clinically significant abnormal lab values as assesses by the investigator.
boolean
C0681902 (UMLS CUI [1,1])
C0205161 (UMLS CUI [1,2])
suicidal behavior; hamilton depression rating scale
Item
10. risk for suicidal behavior based on clinician assessment and a score of greater than 5 on the suicidal thought item of the madrs or a score of 4 on the suicide item of the hamilton depression rating scale.
boolean
C1760428 (UMLS CUI [1])
C0451203 (UMLS CUI [2])
suicide attempt
Item
11. subjects who have had a serious suicide attempt in the past year as assessed by the investigator.
boolean
C0038663 (UMLS CUI [1])
Antidepressant therapy somatic; electroconvulsive therapy; phototherapy
Item
12. current other somatic antidepressant therapy, i.e. vagus nerve stimulation, electroconvulsive therapy, or phototherapy.
boolean
C1096649 (UMLS CUI [1,1])
C2986476 (UMLS CUI [1,2])
C0013806 (UMLS CUI [2])
C0031765 (UMLS CUI [3])
psychotherapy
Item
13. started psychotherapy in the past 30 days.
boolean
C0033968 (UMLS CUI [1])